Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: September 27, 2022

Details for Patent: 6,328,994

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 6,328,994
Title: Orally disintegrable tablets
Abstract:An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Morimoto; Shuji (Suita, JP), Tabata; Tetsuro (Suita, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/355,781
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,328,994
Patent Claim Types:
see list of patent claims
Dosage form; Composition; Formulation;

Drugs Protected by US Patent 6,328,994

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,328,994

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-135472May 18, 1998
Japan10-219266Aug 03, 1998
Japan10-222151Aug 05, 1998
Japan10-344810Oct 29, 1998
Japan11-005144Jan 12, 1999
Japan11-015851Jan 25, 1999
PCT Information
PCT FiledMay 17, 1999PCT Application Number:PCT/JP99/02548
PCT Publication Date:November 25, 1999PCT Publication Number: WO99/59544

International Family Members for US Patent 6,328,994

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 348601 See Plans and Pricing
Australia 3731699 See Plans and Pricing
Canada 2323680 See Plans and Pricing
Canada 2587022 See Plans and Pricing
China 1195500 See Plans and Pricing
China 1311669 See Plans and Pricing
Germany 69934505 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.